-- China National Medicines' (SHA:600511) attributable profit rose 3.3% to 474.3 million yuan in the first quarter from 459 million yuan in the year-ago period, according to a Thursday filing with the Shanghai bourse.
Earnings per share at the pharmaceutical company increased 3.3% to 0.6286 yuan from 0.6084 yuan in the prior-year period.
Operating income grew 6.6% year over year to 13.6 billion yuan from 12.7 billion yuan.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We upgrade our rating to Buy (Hold) and raise the target price to USD16.00 (USD6.50) by rolling forward valuation metrics to 2027 and shifting to P/Sales (P/S) from EV/EBITDA. We apply a 3.25x P/S multiple based on Optical Network peers' five-year average on higher contribution from Optical Networks, stronger AI & Cloud demand visibility, and a more durable growth profile beyond the telecom cycle. The re-rating reflects improving earnings visibility and a structural shift in demand toward AI-driven infrastructure. While Q1 2026 results were in line with expectations, we raise 2026 revenue forecast to EUR21.5B (EUR21.1B) and 2027 to EUR23.3B (EUR22.6B) on higher Network Infrastructure growth guidance, improving supply visibility, and stronger order momentum. This also incorporates early backlog conversion and improving execution in Optical Networks. Hence, we increase 2026 EPS to EUR0.32 (EUR0.31) and 2027 to EUR0.39 (EUR0.37) on revenue mix improvement, with margin expansion expected as scale benefits materialize.
The US Department of the Interior on Wednesday released a final environmental review of a proposal to restart well stimulation, including hydraulic fracturing, at an aging oil platform off the coast of Southern California.The review, conducted by the Bureau of Ocean Energy Management, covers potential environmental impacts of treatments on up to 16 existing wells at Platform Gilda, located in federal waters off Ventura County in the Santa Barbara Channel.The work forms part of an update to the operator's Development and Production Plan for the platform, which has been in operation since 1981.BOEM said publication of the final environmental impact statement does not constitute approval of the proposed activities. The agency is expected to issue a separate record of decision after completing its review of environmental and other relevant considerations.Platform Gilda, operating under Outer Continental Shelf Lease No. P0216 is located about 8.8 miles or 14 kilometers southwest of Ventura, California, in waters about 205 feet deep.The platform, which was installed in 1981, has remained in continuous operation since then.
SEI Investments (SEIC) is viewed as a net "beneficiary" of artificial intelligence, with low risk of "disruption," following a Q1 earnings beat that underscored strong margin expansion and sales momentum, Morgan Stanley said in a report Thursday.The company beat expectations with earnings per share higher by $0.13, or about 10%, as revenue came in roughly 2% above consensus and expenses about 3% lower, while adjusted pre-tax margin reached 32%, the highest "since 2009," and net new sales hit a record $67 million, in part driven by major asset manager wins and reflecting a "diversified pipeline" with further expansion potential, the report said.SEI is positioned to benefit from AI through cost efficiencies and productivity gains across areas such as reconciliation, reporting, compliance and outsourced back-office services, which could support further margin expansion, Morgan Stanley said.The investment bank raised the company's 2026 EPS estimates by $0.52 to $5.87 and 2027 EPS by $0.44 to $6.62, reflecting higher margins and modest revenue upside, while maintaining a positive long-term outlook.Morgan Stanley reiterated an overweight rating on SEI Investments and raised its price target to $113 from $108.Price: $90.53, Change: $+5.74, Percent Change: +6.77%